Ryplazim

Adult Dosing .

Dosage forms:  INJ

plasminogen deficiency, type 1 (hypoplasminogenemia)

[6.6 mg/kg/dose IV q2-4 days]

Start: 6.6 mg/kg/dose IV q3 days; Info: obtain baseline plasminogen activity level (PAL), allow 7-day washout period if receiving FFP, then obtain trough PAL 72h after 1st dose; if trough PAL <10% above baseline PAL, incr. frequency to q2 days x12wk; if trough PAL 10-20% above baseline PAL, cont. frequency q3 days x12wk; if trough PAL >20% above baseline PAL, decr. frequency to q4 days x12wk; if lesions resolve by 12wk, cont. same frequency and evaluate q12wk; if lesions not resolved by 12wk, or new/recurrent lesions, incr. frequency in 1-day increments q4-8wk up to q2 days x12wk, then consider D/C if not achieving desired outcome by 12wk

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Dosage forms:  INJ

plasminogen deficiency, type 1 (hypoplasminogenemia)

[6.6 mg/kg/dose IV q2-4 days]

Start: 6.6 mg/kg/dose IV q3 days; Info: obtain baseline plasminogen activity level (PAL), allow 7-day washout period if receiving FFP, then obtain trough PAL 72h after 1st dose; if trough PAL <10% above baseline PAL, incr. frequency to q2 days x12wk; if trough PAL 10-20% above baseline PAL, cont. frequency q3 days x12wk; if trough PAL >20% above baseline PAL, decr. frequency to q4 days x12wk; if lesions resolve by 12wk, cont. same frequency and evaluate q12wk; if lesions not resolved by 12wk, or new/recurrent lesions, incr. frequency in 1-day increments q4-8wk up to q2 days x12wk, then consider D/C if not achieving desired outcome by 12wk

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]